Deka Bioscience is a three-year-old biotechnology R&D startup focused on the discovery and development of the next generation of cytokine therapies to treat devastating diseases such as cancer, Crohn’s, sepsis, psoriasis, and rheumatoid arthritis. Co-founder & Chief Business Officer Pavel Khrimian explains that Deka used nature as its guide in designing an enhanced manufacturing scaffold platform that extends half-life, targets specific tissues, and delivers disease controlling dual cytokine (Diakine™) combinations directly into affected tissues. Responses to a given cytokine vary. Deka has also developed disease-specific assays to determine who will best respond and benefit from the Diakine therapies.
eLabNext provides a One-Stop Solution for Deka Bioscience
Challenge – So Many Challenges, So Little Time
Solution – eLabNext Stands Out for Research and Development and Day-to-Day Operations
Result – All Challenges Met in a Single Stroke with eLabNext
By implementing eLab, Deka Bioscience was able to streamline its production and testing processes as well as its data management systems.
Pavel Khrimian, Co-founder & CEO